<DOC>
	<DOCNO>NCT02668588</DOCNO>
	<brief_summary>This multicentre , double blind , randomize placebo control trial ass effect LF-PB seroma formation woman breast cancer undergo Axillary Lymph Node Dissection ( ALND ) . Recruited patient randomly assign receive LF-PB 30 mg placebo .</brief_summary>
	<brief_title>Extended-release Octreotide ( LF-PB ) Treatment Seroma</brief_title>
	<detailed_description>The study randomize 24 72 subject receive ALND . A staged adaptive design employ two intermediate analysis final analysis . The first interim analysis 24 treated subject ( least 12 group ) second 48 treated subject ( least 24 group ) .</detailed_description>
	<mesh_term>Seroma</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Signed informed consent form ; Undergoing breast cancer surgery axillary lymph node dissection current clinical trial ; Negative serum pregnancy test woman childbearing potential ; Aspartate aminotransferase alanine aminotransferase &lt; 2 x upper limit normal ; ECOG PS â‰¤ 1 . Previous axillary surgery armpit ( sentinel lymph node surgery exclusionary ) ; Previous radiotherapy within five year study drug administration armpit undergo surgery study ; Concomitant participation clinical trial ; Uncontrolled diabetes ; Cholelithiasis ; Human immunodeficiency virus hepatitis B C screen serology ; Uncontrolled hypothyroidism : patient administer Eutirox/ Levothyroxine ( analogue ) level T3 , T4 TSH confirm within normal range screen , patient enrol study ; Pregnant lactating ; Ascertained presumptive hypersensitivity active principle and/or ingredient study drug formulation ; Corrected QT ( use Bazett formula , QTc ) interval screen baseline &gt; 450 msec ( mean 3 consecutive reading 5 minute apart ) ; Presence disease use concomitant medication know increase QT interval ; Clinically significant relevant abnormal medical history , vital sign , physical examination laboratory evaluation finding ; Corticosteroid treatment longterm basis ( i.e . treatment 3 consecutive day ) ; Current recurrent disease could affect result clinical laboratory assessment require study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>